Side-by-side comparison of AI visibility scores, market position, and capabilities
World's top humanoid robot seller (2025). 5,500 units sold. 1.71B yuan (~$250M) revenue, 335% growth. Filing $610M Shanghai IPO at $7B. Founded 2016, Hangzhou.
Unitree Robotics is a Chinese robotics company founded in 2016 by Wang Xingxing in Hangzhou (Zhejiang province), built on the mission of making advanced legged robots accessible and commercially viable. The company's core technology focuses on high-performance quadruped and humanoid robot hardware — including proprietary actuators, motion control algorithms, and onboard AI inference — at price points significantly below international competitors. Unitree's approach treats robots as mass-market hardware products rather than bespoke research systems, driving rapid iteration and volume production.\n\nUnitree's product line spans quadruped robots (the Go and B series used in inspection, logistics, and research), and its H1 and G1 humanoid robots designed for industrial and service applications. The company became the world's top humanoid robot seller by units in 2025, having sold approximately 5,500 units — a volume achievement that reflects both the accessibility of its pricing and growing enterprise demand for deployable robotic labor. Its robots are used in manufacturing, warehousing, research institutions, and by other AI companies as hardware platforms for embodied intelligence development.\n\nUnitree reported revenue of approximately 1.71 billion yuan (roughly $250 million) in its most recent period, reflecting 335% year-over-year growth driven by surging demand for humanoid robots. The company is pursuing a $610 million IPO on the Shanghai STAR Market at a reported valuation of approximately $7 billion, which would make it one of the most valuable robotics companies in the world at listing. Unitree's combination of production scale, competitive pricing, and rapidly advancing capability gives it a foundational position in the emerging mass-market robotics industry.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.